PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Consensus "Moderate Buy": Six analysts cover PolyPid (five buy, one sell) and the average 12‑month price target is $12.25.
• Shares trade around $4.31 with a market cap of about $82.2M; the company reported quarterly EPS of -$0.41, missing estimates by $0.07, and analysts forecast -1.79 EPS for the year.
• PolyPid is a clinical‑stage biotech using a Mucoadhesive & Mucus‑Penetrating (MMP) polymer drug‑delivery platform, with lead programs including OncoTears, OralTear and Paclical.

PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $12.25.

A number of research firms have recently commented on PYPD. Wall Street Zen upgraded shares of PolyPid from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Weiss Ratings restated a "sell (d-)" rating on shares of PolyPid in a research note on Monday, December 29th. Finally, HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of PolyPid in a research note on Wednesday, February 11th.

Hedge Funds Weigh In On PolyPid

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock worth $32,000 after buying an additional 3,500 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of PolyPid during the 4th quarter worth about $44,000. Jane Street Group LLC acquired a new position in shares of PolyPid during the 4th quarter worth about $66,000. XTX Topco Ltd lifted its stake in PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company's stock valued at $142,000 after purchasing an additional 10,888 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in PolyPid in the 4th quarter valued at about $451,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Stock Performance

Shares of NASDAQ PYPD opened at $4.31 on Monday. The firm has a market cap of $82.23 million, a PE ratio of -1.91 and a beta of 1.45. PolyPid has a 1-year low of $2.44 and a 1-year high of $5.12. The company has a fifty day moving average price of $4.34 and a 200 day moving average price of $4.06.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). Equities research analysts forecast that PolyPid will post -1.79 EPS for the current year.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.